Medical device co IceCure plans Tel Aviv IPO

The company plans to raise NIS 30 million.

IceCure Medical published a draft prospectus today for an offering on the Tel Aviv Stock Exchange. The company intends to raise some NIS 30 million. This draft is the first published by a biomed company after five offerings by such companies were cancelled in the previous quarter.

The company's first product is for the removal of benign growths from the breast. The product obtained US Food and Drug Administration approval last year, and it is also approved for sale in Europe.

Among IceCure's shareholders are Giza (33%), Docor (16%), and Ofer Hi-Tech (11%.

Published by Globes [online], Israel business news - - on January 5, 2011

© Copyright of Globes Publisher Itonut (1983) Ltd. 2011

View comments in rows
Update by email about comments talkback
Your name
Please insert your name
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס MAD Conference 2017